O
3.71
-0.32 (-7.94%)
AIStockmoo 评分
| 价值 30% | 0.0 |
| 来自我们的 AI Insight 报告对预期回报与风险的评估。 参考 | NA |
| 相对估值 参考 | NA |
| 隐含增长 参考 | NA |
| 历史估值 参考 | NA |
| 负债低。盈利能力弱。短期流动性充足。现金流为负。 参考 | |
| 资本回报 参考 | NA |
| 时机 30% | -0.5 |
| 来自我们对走势图的 AI 技术分析。 参考 | NA |
| 过去一年呈上升趋势。股价远低于52周高点。 参考 | |
| K线形态 参考 | NA |
| 您持有期的趋势 参考 | NA |
| 市场情绪 20% | 0.0 |
| 近期没有目标价,因此依据目标价的调整方向。 参考 | |
| 新闻情绪 参考 | NA |
| 聪明钱 20% | 3.2 |
| 内部交易活动 参考 | NA |
| 机构在最新13F申报中净+18.26%的股份:56家增持,23家减持(截至30 Sep 2026的季度)。 参考 | |
| 空头持仓从31 Aug到30 Oct 2026变化+16.4%,回补天数11.3天(FINRA)。 参考 | |
| 市场和行业状况不佳。 | |
| 市场环境偏谨慎。 参考 | |
| 行业表现落后大市。 | |
| 各支柱方向一致,评分因此加强。 | |
| 不计入评分 | |
| 股价接近其52周平均水平。5年来下跌。 参考 | |
| 短期动能下降。 参考 | |
| 股价处于支撑位与阻力位之间。支撑与阻力水平趋降。 参考 | |
| 最终评分 | 0.46 |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 看涨 |
| Biotechnology (全球的) | 混合的 | 看涨 | |
| 股票 | Oramed Pharmaceuticals Inc. | 混合的 | 混合的 |
相关股票
| 股票 | 市值 | DY | P/E(TTM) | P/B |
|---|---|---|---|---|
| ORMP | - | 6.74% | - | 0.530 |
| OPT | 583 M | - | - | 4.31 |
| OCUP | 51 M | - | - | 0.870 |
| CTMX | - | - | - | 1.55 |
| ZYME | - | - | - | 7.29 |
| PBYI | - | - | - | 2.73 |
|
Oramed Pharmaceuticals Inc is a pharmaceutical company that is engaged in the research and development of pharmaceutical solutions with a technology platform that allows for the oral delivery of therapeutic proteins. The company has developed an oral dosage form intended to withstand the harsh environment of the gastrointestinal tract and effectively deliver active insulin or other proteins. Its product pipeline includes ORMD-0801 for Diabetes, ORMD-0801 for NASH, and ORMD 0901. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Core |
| 内部持股比例 | 13.21% |
| 机构持股比例 | 19.12% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Sb Capital Management Inc | 31 Dec 2025 | 1,900,000 |
该时间范围内无数据。
该时间范围内无数据。
机构
机构持股比例: 46.16%
| 持仓变动 | 机构数 | 股数 |
|---|---|---|
| 增持 | 56 | 6,335,923 |
| 减持 | 23 | 704,680 |
| 新建仓 | 23 | 2,573,118 |
| 清仓 | 8 | 350,717 |
来源:经Nasdaq的SEC 13F申报,最新申报截至30 Sep 2026。申报在每季结束后45天内陆续提交。
空头持仓
| 结算日 | 股数 | 回补天数 |
|---|---|---|
| 30 Oct 2026 | 1,343,457 | 11.3 |
| 15 Oct 2026 | 1,451,095 | 10.4 |
| 30 Sep 2026 | 1,433,436 | 7.3 |
| 15 Sep 2026 | 1,307,745 | 7.4 |
| 31 Aug 2026 | 1,154,241 | 4.3 |
| 14 Aug 2026 | 1,025,767 | 5.9 |
来源:经Nasdaq的FINRA空头持仓数据,每月公布两次。
0 正面
0 负面
1 中性
| 日期 | 类型 | 细节 |
|---|---|---|
| 12 Nov 2026 | Yahoo Finance |
Oramed: Q3 Earnings Snapshot
NEW YORK (AP) — NEW YORK (AP) — Oramed Pharmaceuticals Inc. (ORMP) on Thursday reported profit of $134… |
| 08 Sep 2026 | Yahoo Finance |
Lifeward Publishes Updated Investor Presentation Highlighting Commercial Growth Strategy
HUDSON, Mass. and YOKNEAM ILLIT, Israel, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Lifeward Ltd. (Nasdaq: LFWD) (“Lifeward” or the “Company”), a diversified biomedical innovation company with a portfolio of commercialized neurorehabilitation products and a biomedical pipeline, today announced that an… |
| 28 Aug 2026 | Yahoo Finance |
ORMP: Investment Gains Contributed to Strong 2Q26 EPS, While Inclusion in Russell Indexes Arguably Boosts Awareness
By M. Marin NASDAQ: ORMP READ THE FULL ORMP RESEARCH REPORT Gains on investment portfolio + service agreement income contributed to 2Q26 EPS of $2.76 Oramed Pharmaceuticals (NASDAQ: ORMP) leverages its strong balance sheet, with $15.2 million of cash and equivalents and $50.6 million of cash and… |
| 17 Aug 2026 | Yahoo Finance |
Nano Dimension Appoints Nadav Kidron to Board of Directors to Chair Strategy and Capital Allocation Committee
WALTHAM, Mass., Aug. 17, 2026 (GLOBE NEWSWIRE) -- Nano Dimension Ltd. (Nasdaq: NNDM) (“Nano Dimension,” “Nano,” or the “Company”) today announced the appointment of Nadav Kidron to its Board of Directors (the “Board”). As part of the Board’s ongoing strategic review, led by Chairman Phillip… |
| 股息率 (DY TTM) | 6.74% |
| 预计下次股息支付 | Jan 2027 |
| 除息日 | 公告日期 | 支付日期 | 详情 |
|---|---|---|---|
| 16 Jan 2026 | - | 26 Jan 2026 | 0.25 现金 |
每年股息收益率
| 年份 | 每年总股息 ($) | 频率/年份 | 收益率 % |
|---|---|---|---|
| 2026 | 0.250 | 1 | 6.74 |
投资组合